Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Kymera Therapeutics, Inc.